Braveheart Bio, Inc.
BRVE
NASDAQ26.75
USD
-0.91
- -
Braveheart Bio, Inc.
BRVE
(NASDAQ)
Recent
price
26.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Braveheart Bio, Inc. engages in the discovery, development, and commercialization of biomedical products and life sciences solutions focused on advancing human health through precision biology and therapeutic innovations. The company provides a portfolio of products and services including protein engineering platforms; diagnostic and biomarker discovery capabilities; preclinical and translational research services; contract research outsourcing for pharmaceutical and biotechnology clients; and data-driven decision support tools powered by genomic and proteomic analytics. Braveheart Bio operates across multiple geographic regions, with research and development, manufacturing, and commercialization activities in North America, Europe, and Asia-Pacific, supported by a network of collaborators, contract manufacturing organizations, and strategic partners. Founded in 2020 and headquartered in Boston, Massachusetts, Braveheart Bio maintains subsidiaries and affiliate entities to support regional operations and go-to-market activities in targeted markets. The company pursues strategic partnerships, licensing agreements, and potential acquisitions to augment its core capabilities and expand its service offerings; it also pursues funding rounds to support pipeline advancement and platform expansion. Braveheart Bio’s target customers include pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations seeking advanced biotechnologies, analytical services, and translational research support. Main products and services are organized around core platforms and service types, including: protein engineering and optimization services; biomarker discovery and validation services; genomic and proteomic analytics platforms; preclinical pharmacology and toxicology testing services; contract research and development outsourcing across small molecule and biologics programs; manufacturing process development and scale-up for biologics and biologics-derived products; data analytics and decision support tools for portfolio and program management; strategic collaborations and licensing options for platform access and co-development opportunities. Braveheart Bio emphasizes a science- and data-driven approach to accelerate drug discovery, with ongoing emphasis on expanding its platform capabilities, expanding geographic reach, and forming strategically beneficial alliances to enhance its growth trajectory. The company’s operations reflect a focus on Europe and Asia-Pacific expansion alongside its U.S. activities, positioning it to serve global customers with integrated research, development, and manufacturing solutions. The description above reflects Braveheart Bio, Inc. (BRVE) as per the latest publicly available information and corporate disclosures.
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock
Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
Braveheart Bio Readies $300 Million IPO Plan